Back to results
US 2021/0330665 A1Published application
Pharmaceutical formulations
AssigneeAstraZeneca AB
InventorFarhan Abdel Karim Mohammad AL HUSBAN
Life of this patent
Estimating the term…
Abstract
The present specification relates to pharmaceutical formulations comprising N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA), for example tablets with immediate release properties.
Claims28
A pharmaceutical formulation comprising N-(1-(3-fluoropropyl)-azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose, and dicalcium phosphate anhydrous.
Dependencies are inferred from the claim text.